CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 1 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Title Page  
Protocol Title :  
A Randomized, Double -Blind, Single and Multiple Ascending Dose Study to Assess the Safety 
and Pharmacokinetic s of ANA 001 in Healthy Adults  
Protocol Number : ANA001 -002.02 
Compound Number:  ANA 001 
Short Title:  
A single ascending dose (SAD) and multiple ascending dose (MAD) PK study of ANA 001in 
healthy adults  
Sponsor  Name and Legal Registered Address:   
ANA Therapeutics, Inc .  
602 Bainbridge St.  
Foster City, CA 94404 USA  
 
Regulatory Agency Identifying Number (s):  
IND #148459  
 
Protocol Finalization Date: 09 January 2021  
Version: 2.0 
 
 
 
Confidentiality Statement  
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y not be disclosed 
unless such disclosure is required by applicable law or regulations. In any event, persons to whom the informati on is disclosed must be informed 
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 2 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  that the information is privileged  or confidential  and may not be further disclosed by them. These restrictions on disclosure will apply equally to 
all future information supplied to you that is indicated as privileged  or confidential .  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 3 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  INVESTIGATOR  AGREEMENT  
This protocol was designed and will be conduct ed, recorded, and reported in compliance with the 
principles of Good Clinical Practice (GCP) guidelines.  These guidelines are stated in U.S. 
federal regulations, as well as the “Guideline for Good Clinical Practice,” International 
Conference on Harmonizat ion of Technical Requirements for Registration of Pharmaceuticals 
for Human Use.  
I have read this protocol and agree that it contains all necessary details for carrying out this 
study. I will conduct the study as outlined herein and will complete the stud y within the time 
designated.  
I will provide copies of the protocol and all pertinent information to all individuals responsible to 
me who assist in the conduct of the study. I will discuss this material with them to ensure they 
are fully informed regardin g the study drug and the conduct of the study.  
Principal Investigator  
Name:  Helen Paguntalan , MD  
Institution and Address:  WCCT Global  
5630 Cerritos Ave.  
Cypress, CA 90630  
Telephone number:  714-252-0700  
Signature: ____________________________________ ____________ _________ _ Date : ______ _______________  
          (Day Month Year)  
 
Sponsor ’s Responsible Medical Officer:  
Name:  Doug Rank, MD , Vice President of Clinical Development  
Institution and Address:  ANA Therapeutics, Inc.  
602 Bainbridge St.  
Foster City, CA 94404 USA  
Telephone number:  415-990-4073  
Signature: ____________________________________ ____________ _________ _ Date : ______ _______________  
          (Day Month Year)  
  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 4 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  STUDY ADMINISTRATION  
Study Role  Name, title, contact information  
Sponsor  ANA Therapeutics, Inc.  
602 Bainbridge St.  
Foster City, CA 94404 USA  
Principal Investigator   Helen Paguntalan , MD  
WCCT Global  
5630 Cerritos Ave.  
Cypress, CA 90630  USA  
Medical Monitor  Doug Rank, MD  
602 Bainbridge St.  
Foster City, CA 94404 USA  
Biostatistics and 
Pharmacokinetics  Kalyan Ghosh, PhD  
Inference, Inc.  
701 Lee Rd.  
Chesterbrook, PA 19087 USA  
Clinical  laboratory  Innovative Bioanalysis, LLC  
5630 Cerritos Ave.  
Cypress, CA 90630 USA  
Bioanalytical  laboratory  
(PK-analysis)  Medpace  Bioanalytical Laboratories  
5375 Medpace Way  
Cincinnati, Ohio 45227 USA  
Tel: 513-579-9911  
Fax: 513-579-044 
 
  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 5 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Protocol Amendment History  
Date  Description  
24-Dec-20 Amendment 1  
 The protocol is amended to address  comments received by the FDA as follows:  
 - Revising the Inclusion  criteria  pulse rate limits from 40 -100 bpm to 50 – 100 bpm 
 - Providing reference laboratory values that will be used to de termine if  laboratory  results ar e considered 
clinically significant  
 - Provi ding a standard toxicity grading scale  
 - Provi ding of detailed individual and dose level stopping criteria based upon the known safety profile and 
mechanism of action of ANA001 (niclosamide)  
 - Limiting the total daily dose in the MAD portion of the protocol to 2 000 m g 
 Page 8. MAD  
Total daily doses  are anticipated to range between  will not exceed 2000 mg and  4500 mg  of ANA001.  
 Page 18. Section 3.3 Benefit/Risk Assessment  
The current SAD/MAD study is designed to explore the safety and PK of dosing greater than  up to 2000 3000  
mg/day as a single dose and regimens not to exceed 2000 mg/day  as divided doses BID or TID.  
 Page 20 . MAD  
Total daily doses  are anticipated to range between  will not exceed 2000 mg and 4500 mg  of ANA001.  
 Page 21 . Section  5.5 Justification for Dose  
The current study is designed to assess the safety of single doses of ANA001  exceeding  up to 3000 2,000  mg 
and multiple dosing regimens up to  not to exceed 2000 mg daily divided either BID or TID.  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 6 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Date  Description  
24-Dec-20 Amendment 1  
 Page 22 . Section  6.1 Inclusion Criteria  
 6. Pulse rate between 40 50 and 100 beats per minute (bpm)  
 Page 23. Section 6.2 Exclusion Criteria  
Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening as deemed 
appropriate by the Investigator  assessed per Appendix 6 . 
 Page 25 . 7.2 Dose Modification  
 Following review of the safety and PK data of three SAD cohorts, a fourth cohort may be added, not to exceed 
4500 mg.  
Total daily doses are anticipated to be between  will not exceed 2000  mg and 4500 mg . 
 Page 31. Section 9.1.4 Clinical Safety Laboratory Assessments  
The Investigator must review the laboratory report, document this review, and record any clinically relevant 
changes (as per the reference laboratory values [Appendix 6]) occurring during the study in the AE section of 
the CRF.  
All laboratory tests with va lues considered clinically significantly abnormal during participation in the study 
should be repeated until the values return to normal or baseline or are no longer considered clinically significant 
by the Investigator or medical monitor as per the refere nce laboratory values in Appendix 6.  
If laboratory values from non -protocol specified laboratory assessments performed at the institution’s local 
laboratory require a change in participant management or are considered clinically significant by the Investig ator 
as given in Appendix 6 (e.g., SAE or AE or dose modification), then the results must be recorded in the CRF.  
 Page 33 .  Insertion of 9.3 Stopping Rules in Response to SAE  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 7 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Date  Description  
24-Dec-20 Amendment 1  
 Dose -limiting toxicity AEs will be defined as Grade ≥3, treatment -emergent, treatment -related laboratory 
abnormalities (Appendix 6) or AEs per the grading system  by US Department of Health and Human Services  
(CTCAE, Version 5.0) . 
 The following Stopping Criteria will be used:  
 Clinical Findings:  
 1. Anaphylaxis or Grade ≥3 skin rash or pruritis  
 2. Grade ≥3 nausea, emesis or diarrhea  
 Laboratory Findings:  
 1. Evidence of new onset of acute renal or hepatic failure, defined by increases in BUN, creatinine, or LFTs 
(AST, ALT, Alkaline phosphatase) that reflect new evidence of Grade 3 thresholds for liver function tests, 
for creatinine, and for electrolytes attrib utable to the administration of drug in the context of the 
Investiga tor’s evaluation.  
 2. Evidence of acute infection or inflammation, defined by changes in the WBC and differential indices , 
attributable to the administration of drug in the context of the Investigator’s evaluation.  
 3. Any “unexpected” Grade ≥3 Laboratory test result.  
  If one of the above clinical or laboratory criteria for stopping occurs in any subject, further study recruitment and 
subject dosing will be halted  until a full safety assessment can be completed .  Unblinding of the affected subject 
will be performed and the PI and Sponsor will review the totality of clinical data and any other circumstances 
possibly  related to the “Stopping Criteria” findings  to determine if the study can be resumed, modified, or will 
be permanently terminated .  
 Page 33. Section 9.3 Treatment of Overdose  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 8 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Date  Description  
24-Dec-20 Amendment 1  
For this study, any dose of ANA001 greater than 4500  3000  mg within a 24-hour time period will be considered 
an overdose.  
 Page 37. Section 11 References  
Inserted reference in relation to Stopping rules: US Department of Health and Human Services. Common 
Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Publishe d: November 27, 2017.  
 Page 50. Appendix 4  
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments 
(e.g., ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered 
clinically significant in the medical and scientific judgment of  by the Investigator per Appendix 6  (i.e., not 
related to progression of underlying disease).  
 Insertion of Appendix 6  Potentially Clinically Significant Laboratory Criteria  
 Editorial Changes  
 Language in bold has been added to the document for clarification purposes. Minor formatting and typographical errors 
were corrected throughout the protocol.  
 Page 7. Section 1 Synopsis  and Page 15. Section 3.1 Study Rationale  
ANA001 is a new formulation containing 250 mg nic losamide per capsule. Although other formulations 
containing  niclosamide (ANA001) have  been studied for tapeworm infections and other potential human uses, 
limited systemic PK/PD data exists in the literature. To ensure proper systemic levels of niclosamid e are 
achieved for therapeutic effect, a SAD/MAD study with ANA001 capsules  is necessary . 
 Page 7. Section 1 Synopsis  
ANA001 capsule containing  250 mg niclosamide , administered orally as 4, 6, 8 or 12 capsules with a light meal 
(500 to 750 cal) or snack.  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 9 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Date  Description  
24-Dec-20 Amendment 1  
All participants on active treatment who contributed at least one post dose blood sample , evaluable for drug  PK 
concentration will be included in the PK analysis.  
 Global change throughout protocol  
Replaced ‘postdose’ with ‘after dosing’ and ‘predose’ with ‘before dosing’ expect with analysis timepoints . 
 Page 14. Section 3 Introduction  
Due to its pleiotropic pharmacologic activity, niclosamide has been and is being  continues to be  studied in for a 
variety of other clinical indications.  
COVID -19 is results in  a cytokine release syndrome.  
 Page 43. Appendix 1  
Updated as per changes in text. 
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 10 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Table of Contents  
 
Protocol Amendment History  ................................ ................................ ................................ .......5 
1. Synopsis ................................ ................................ ................................ .......................... 13 
2. Schedule of Activities (SoA)  ................................ ................................ ......................... 16 
3. Introduction  ................................ ................................ ................................ ................... 20 
3.1. Study Rationale  ................................ ................................ ................................ ............... 21 
3.2. Background  ................................ ................................ ................................ ..................... 21 
3.2.1.  Chemical Name/Structure  ................................ ................................ ............................... 22 
3.2.2.  Nonclinical Studies  ................................ ................................ ................................ ......... 22 
3.2.3.  Safety  ................................ ................................ ................................ .............................. 23 
3.3. Benefit/Risk Assessment  ................................ ................................ ................................ 24 
4. Objectives and Endpoints  ................................ ................................ ............................ 25 
5. Study Design  ................................ ................................ ................................ .................. 26 
5.1. Overall Design  ................................ ................................ ................................ ................ 26 
5.2. Participant and Study Completion  ................................ ................................ .................. 27 
5.3. End of Study Definition  ................................ ................................ ................................ ..27 
5.4. Scientific Rationale for Study Design  ................................ ................................ ............ 27 
5.5. Justification for Dose  ................................ ................................ ................................ ......27 
6. Study Population  ................................ ................................ ................................ ........... 28 
6.1. Inclusion Criteria  ................................ ................................ ................................ ............ 28 
6.2. Exclusion Criteria  ................................ ................................ ................................ ........... 29 
6.3. Lifes tyle Restrictions  ................................ ................................ ................................ ......30 
6.3.1.  Meals and Dietary Restrictions  ................................ ................................ ....................... 30 
6.3.2.  Caffeine, Alcohol, and Tobacco  ................................ ................................ ..................... 30 
6.3.3.  Activity  ................................ ................................ ................................ ........................... 30 
6.4. Screen Failures  ................................ ................................ ................................ ................ 30 
7. Treatments  ................................ ................................ ................................ ..................... 31 
7.1. Treatments Administered  ................................ ................................ ................................ 31 
7.2. Dose Modification  ................................ ................................ ................................ .......... 31 
7.3. Method of Treatment Assignment  ................................ ................................ .................. 31 
7.4. Blinding  ................................ ................................ ................................ .......................... 31 
7.5. Preparation/Handling/Storage/Accountability  ................................ ................................ 32 
7.6. Treatment Compliance  ................................ ................................ ................................ ....32 
7.7. Concomitant Therapy  ................................ ................................ ................................ .....32 
7.7.1.  Rescue Medicine  ................................ ................................ ................................ ............. 33 
7.8. Treatment after the End of the Study  ................................ ................................ .............. 33 
8. Discontinuation/Withdrawal Criteria  ................................ ................................ ......... 34 
8.1. Discontinuation of Study Treatment  ................................ ................................ ............... 34 
8.2. Withdrawal from the Study ................................ ................................ ............................. 34 
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 11 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  8.3. Lost to Follow Up  ................................ ................................ ................................ ........... 34 
9. Study Assessments and Procedures ................................ ................................ ............. 35 
9.1. Safety Assessments  ................................ ................................ ................................ ......... 36 
9.1.1.  Physical Examinations  ................................ ................................ ................................ ....36 
9.1.2.  Vital Signs  ................................ ................................ ................................ ....................... 37 
9.1.3.  Electro cardiograms  ................................ ................................ ................................ ......... 37 
9.1.4.  Clinical Safety Laboratory Assessments  ................................ ................................ ........ 37 
9.2. Adverse Events  ................................ ................................ ................................ ............... 38 
9.2.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ................................ ..................... 38 
9.2.2.  Method of Detecting AEs and SAEs  ................................ ................................ .............. 38 
9.2.3.  Follow -up of AEs and SAEs  ................................ ................................ ........................... 38 
9.2.4.  Regulatory Reporting Requirements for SAEs  ................................ ............................... 39 
9.2.5.  Pregnancy  ................................ ................................ ................................ ........................ 39 
9.3. Stopping Rules in Response to SAEs or Other Events  ................................ ................... 39 
9.4. Treatment of Overdose  ................................ ................................ ................................ ...40 
9.5. Pharmacokinetics  ................................ ................................ ................................ ............ 40 
9.6. Medical Resource Utilization and Health Economics  ................................ .................... 41 
10. Statistical Considerations  ................................ ................................ ............................. 42 
10.1.  Sample Size Determination  ................................ ................................ ............................ 42 
10.2. Populations for Analyses  ................................ ................................ ................................ 42 
10.3.  Statistical Analyses  ................................ ................................ ................................ ......... 42 
10.3.1.  Safety Analyses  ................................ ................................ ................................ ............... 42 
10.3.2.  Pharmacokinetic Analyses  ................................ ................................ .............................. 43 
10.3.3.  Interim Analyses  ................................ ................................ ................................ ............. 43 
11. References  ................................ ................................ ................................ ...................... 44 
12. Appendices  ................................ ................................ ................................ ..................... 49 
Appendix 1: Abbreviations and Terms  ................................ ................................ .......................... 50 
Appendix  2: Clinical Laboratory Tests  ................................ ................................ .......................... 53 
Appendix 3: Study Governance Considerations  ................................ ................................ ............ 54 
Regulatory and Ethical Considerations  ................................ ................................ ................. 54 
Financial Disclosure  ................................ ................................ ................................ .............. 54 
Informed Consent Process  ................................ ................................ ................................ ....54 
Data Protection  ................................ ................................ ................................ ...................... 55 
Dissemination of Clinical Study Data  ................................ ................................ ................... 55 
Data Quality Assurance  ................................ ................................ ................................ ........ 56 
Source Documents  ................................ ................................ ................................ ................ 57 
Study and Site Closure  ................................ ................................ ................................ .......... 57 
Appendix 4 : Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ............ 58 
Appendix  5: Contraceptive Guidan ce and Collection of Pregnancy 
Information  ................................ ................................ ................................ ..................... 64 
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 12 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Appendix 6: Potentially Clinically Significant Laboratory Criteria  ................................ .............. 68 
  
List of Tables  
Table 1  Schedule of Activities for SAD  ................................ ................................ .........  16 
Table 2  Schedule of Activities for MAD  ................................ ................................ ....... 17 
Table 3  Schedule of PK Sampling for MAD  ................................ ................................ . 19 
Table 4   Protocol -Required Safety Laboratory Assessments  ................................ .........  53 
Table 5:   Highly Effective Contraceptive Methods  ................................ .........................  65 
 
List of Figures  
Figure 1  Phylogenetic Tree Showing Antiviral Effects of Niclosamide Against Various 
Virus Families  ................................ ................................ ................................ .... 21 
 
 
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 13 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  1. Synopsis  
Protocol Title:  A Randomized, Double -Blind, Single and Mul tiple Ascending Dose Study to 
Assess the Safety and Pharmacokinetics of ANA001 in  Healthy Adults  
Short Title:  A single ascending dose (SAD) and multiple ascending dose (MAD) PK study of 
ANA 001 in healthy adults  
Rationale : 
ANA001 is a new formulation containing 250 mg niclosamide per capsule. Although  other 
formulations containing  niclosamide (ANA001) ha ve been studied for tapeworm infections and 
other potential human uses, limited systemic PK/PD data exists in the literatur e. To ensure proper 
systemic levels of niclosamide are achieved for therapeutic effect, a SAD/MAD study  with 
ANA001 capsules  is necessary . 
Objectives and Endpoint s 
Objectives  Endpoints  
Primary   
• To assess safety and tolerability of 
single oral daily dose s of ANA001 
(1000 mg, 2000 mg and 3000 mg)  
• To assess safety and tolerability of 
multiple daily oral doses ( twice daily 
[BID] or thrice daily [ TID]) of 
ANA001 for 7 days  • Incidence of adverse events (AEs), 
serious AEs (SAEs), study drug 
discontinuation  due to an AE  (MAD 
portion only), use of concomitant 
medications,  and change from baseline 
in clinical laboratory tests, vital signs, 
electrocardiograms (ECG), and 
physical examinations  
Secondary   
• To assess the PK of single and 
multiple do ses of ANA001  • AUC 0-t, AUC 0-last, AUC 0-∞ (SAD 
only), Cmax, tmax, t1/2, CL/F, V z/F 
Overall Design : 
This is a randomized, double -blind study to  be conducted in two parts: single ascending dose 
(SAD) and multiple ascending dose (MAD).  Potential participants for each part will undergo 
screening procedures within 30  days of enrolment.  
SAD  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 14 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  On Day -1, eligible participants will be randomly assigned t o active drug or placebo in an 8:2 ratio. 
On Day 1, following an overnight fast of at least 10 hours, participants will receive their assigned 
treatment (1000 mg, 2000 mg, or 3000 mg of ANA001) with a standardized light meal  (500 to 
750 cal).  A baseline E CG will be performed at Screening  and at 3 hours after dosing . Blood 
pressure and he art rate will be measured  every 8 hours while confined to the clinic. Blood for PK 
will be collected before dosing  and at 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h ours after dosing . Participants 
will be discharged on Day 2 following the 24 -hour PK sample and completion of clinical 
laboratory tests and physical examination. They will return on Day 7 (±2) for follow -up procedures 
including physical examination, laboratory tests,  and assessment of AEs and concomitant 
medication use.  
MAD  
On Day -1, eligible participants will be randomly assigned to active drug or placebo in a 10:2 ratio 
on a BID (q12h) or TID (q8h) schedule , to be determined based on the PK results of the SAD 
cohor ts. Total daily doses will not exceed  2000 mg of ANA001 . On Day s 1 through 7 , participants 
will receive their assigned treatment in the morning with a standardized light meal (500 to 750 cal) 
following an overnight fast of at least 10 hours. Afternoon or e vening doses will be given with a 
light snack . A baseline ECG will be performed at Screening and at 3 hours after the second dose 
on Day 7. Blood  pressure and heart rate will be measured every 8 hours while confined to the 
clinic.  
During BID dosing, b lood for PK will be collected on Days 1 and 7 before dosing  and at 0.5, 1, 2, 
4, 6, 8, 10, and 12 hours after dosing . Blood samples will also be collected on Days 2, 4, 6, and 8 
before dosing  and before the  12 hour dose on Days 2, 4, and 6.  
During TID dosing, blood for PK will be collected on Days 1 and 7 before dosing  and at 0.5, 1, 2, 
4, 6, and 8 hours after dosing . Blood samples will also be collected on Days 2, 4, 6, and 8 before 
dosing , and before the 8 ho ur dose on Days 2, 4, and 6, and  before the  16 hour dose on Day 6 . 
Participants will be discharged on Day 8 following the last PK sample and completion of clinical 
laboratory tests and physical examination. They will return on Day 15 (±2) for follow -up 
procedures including physical examination, laboratory tests, and assessment of AEs and 
concomitant medication use.  
Number of Participant s: 
A minimum of  30 participants will be enrolled in the SAD part and  up to  36 participants in the 
MAD part.  At least 3 part icipants of each sex will be included in each cohort.  
Treatment Groups  and Duration : 
SAD  
Cohort S1: 1000 mg (n=8) or placebo (n=2) , single dose  
CONFIDENTIAL   ANA Therapeutics , Inc.  
Protocol  ANA001 -002.02  
Page 15 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
CONFIDENTIAL  Cohort S2: 2000 mg (n=8) or placebo (n=2) , single dose  
Cohort S3: 3000 mg (n=8) or placebo (n=2) , single dose 
MAD  
Cohort M1 : xx mg (n=9) or placebo (n=3) BID or TID  for 7 days  
Cohort M2 : xx mg (n=9) or placebo (n=3) BID or TID  for 7 days  
Cohort M3: xx mg (n= 9) or placebo (n= 3) BID  or TID  for 7 days  
Investigational Product, Dose, and Mode of Administration  
ANA001 capsule  containing  250 mg  niclosamide , administered orally as 4, 6, 8 or 12 capsules 
with a light meal (500 to 750 cal) or snack.  
Statistical Methods  
Sample Size Determination:  
Sample size was not based on statistical considerations.  
Safety Analysis:  
All participants who received at least one dose of study drug will be included in the safety analysis. 
Safety will be assessed by the incidence and frequency of AEs, and changes in physical 
examinations, vital signs, clinical laboratory te sts, and ECGs . Results will be summarized using 
descriptive statistics (mean, standard deviation [SD], coefficient of variation [%CV], median, 
minimum, maximum).  
Pharmacokinetic Analysis:  
All participants on active treatment who contributed at least one po st dose blood sample,  evaluable  
for drug  PK concentration will be included in the PK analysis. PK parameters, calculated using 
non-compartmental models, include AUC 0-∞, AUC 0-t, AUC 0-last, Cmax, tmax, t1/2, CL/F, and V z/F. 
Results will be summarized using d escriptive statistics (mean, standard deviation [SD], coefficient 
of variation [%CV], median, minimum, maximum). Plasma concentration -time profiles will be 
plotted.  
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 16 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 2. Schedule of Activities  (SoA)  
Table 1 Schedule of Activities for SAD  
  Screening  In-Patient  Discharge  Follow -
up 
Study Day   -30 to -2 -1 1 2 7±2 
Study Procedures    
COVID Pre -screen informed consent  X         
Full study informed consent  X         
Medical history  X         
Prior medications  X         
Physical examination  X         
Abbreviated PE    X X X X 
Viral Serology (HIV, HCV, HBV)  X         
Urine a lcohol and drug screen  X X       
Inclusion / exclusion criteria  X X       
Pregnancy test for WOCBP  X X       
Randomization    X       
CPU Admission & Confinement    X X     
CPU Discharge        X   
Drug Administrationa    X     
Vital signsb X X X  X X 
Height  X         
Weight  X X       
ECGc X  X      
Hematology  X X   X X 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 17 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
   Screening  In-Patient  Discharge  Follow -
up 
Study Day   -30 to -2 -1 1 2 7±2 
Study Procedures    
Serum chemistry  X X   X X 
Urinalysis  X     X X 
Pharmacokineticsd     X X   
Adverse events    Continuous  
Concomitant medications    Continuous  
WOCBP = woman of child -bearing potential  
a.) Administered with Standardized light meal      
b.) Blood pressure and heart rate supine for 3 to 5 mins and every 8 hours during CPU confinement  
c.)  Supine for 5 mins  at Screening and 3 hours after dosing   
d.) 4 mL  before dosing  and 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 hr after 
dosing     
 
Table 2 Schedule of Activities for MAD 
  Screening  Confinement/Treatment Period  Discharge  Follow -up 
Study Day  -30 to -2 -1 1 2 3 4 5 6 7 8 D15±2  
Study Procedures    
COVID Pr e-screen ICF  X                     
Full study informed consent  X                     
Medical history  X                     
Prior medications  X                     
Physical examination  X                     
Abbreviated PE    X   X     X     X X 
Viral Serology (HIV, HCV, 
HBV)  X                     
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 18 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
   Screening  Confinement/Treatment Period  Discharge  Follow -up 
Study Day  -30 to -2 -1 1 2 3 4 5 6 7 8 D15±2  
Study Procedures    
COVID Surveillance (ELISA)    + Swab      X     X       
Urine a lcohol and drug screen  X X                   
Pregnancy test for WOCBP  X X                   
Inclusion / exclusion criteria  X X                   
Randomization    X                   
CPU Admission & Confinement    X X X X X X X X     
CPU Discharge                    X   
Drug Administrationa     X X X X X X X     
Vital signsb X X X  X X X X X X X X 
Height  X                     
Weight  X                     
ECGc X                X     
Hematology  X X   X     X     X X 
Serum chemistry  X X   X     X     X X 
Urinalysis  X     X     X     X X 
Pharmacokineticsd     X X X X X X X X   
Adverse events    Continuous  
Concomitant medications    Continuous  
WOCBP = woman of child -bearing potential  
a.) Administered with standardiz ed light meal  (500 to 750 cal)  in AM and light snack (PM) if BID (q12h) or TID (q8h) daily on days 1 through 6 
and a single AM dose on day 7  
b.) Blood pressure and heart rate supine for 3 to 5 mins and every 8 hours during confinement  
c.) Supine for 5 mins at Screening and at 3 hours after second dose on Day 7  
d.)  see Table 3 
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 19 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Table 3 Schedule of PK Sampling for MAD  
 PK Sampling (4 mL)  Study Day BID Dosing  
Time (hr)  1 2 3 4 5 6 7 8 
Pre-dose Xa Xa   Xa   Xa Xa Xa 
0.5 X           X   
1 X           X   
2 X           X   
4 X           X   
6 X           X   
8 X           X   
10 X           X   
12 X Xa   Xa   Xa Xa   
         
  PK Sampling  (4 mL)  Study Day TID Dosing  
Time (hr)  1 2 3 4 5 6 7 8 
Pre-dose Xa Xa   Xa   Xa Xa Xa 
0.5 X           X   
1 X           X   
2 X           X   
4 X           X   
6 X           X   
8 X Xa   Xa   Xa Xa   
a Pre-dose 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 20 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 3. Introduction  
Niclosamide is a chlorinated salicylanilide with anthelmintic, antiviral and anti -inflammatory 
activity being developed as a potential treatment for COVID -19. Niclosamide was discovered in 
1958, and was approved by the Food and Drug Administration (FDA) in  1982 under New Drug 
Application (NDA) 018669 (Bayer Pharmaceuticals) for the treatment of tapeworm infections, 
although it has since been voluntarily discontinued from marketing in the United States by Bayer. 
Niclosamide is approved in several other count ries for the treatment of tapeworm infections and is 
on the World Health Organization's List of Essential Medicines. Due to its pleiotropic 
pharmacologic activity, niclosamide has been and continues to be  studied for a variety of other 
clinical indications .  
ANA Therapeutics is developing ANA001, an orally administered niclosamide formulation 
containing 250 mg niclosamide per capsule, to treat adult patients with coronavirus disease of 2019 
(COVID -19). COVID -19 results in a cytokine release syndrome ( Hirano and Murakami, 2020 ) 
that is associated – amongst others - with acute respiratory distress syndrome (ARDS), a 
widespread inflammation in the lungs, and increased blood clotting . Niclosamide is a promising 
oral therapeutic which ha s both antiviral and anti -inflammatory properties and a long history of 
safety in humans.   
Niclosamide has broad in vitro  antiviral activity ( Fan et al., 2019 , Andersen et al., 2019 , Jurgeit et 
al., 2012 , Mazzon et al., 2019 , Xu et al., 2020 , Wu et al., 2004 , Wen et al., 2007 , Gassen et al., 
2019 ) including activity against severe acute respiratory syndrome coronavirus 2 (SARSCoV -2) 
with a half -maximal inhibitory concentration (IC 50) of 0.15 -0.28 µM (49 -92 ng/mL) ( Shi, 2020 , 
unpublished data, Jeon et al., 2020 , Gassen et al., 2020 ). Additionally, niclosamide has in vitro  
anti-inflammatory properties due to its inhibition of nuclear factor kappa -light-chain  enhancer of 
activated B cells (NF -κB) and signal transducer and activator of tra nscription 3 (STAT3), two 
main drivers to induce the expression of proinflammatory cytokines. NF -κB and STAT3 were 
inhibited by niclosamide with an IC 50 of 0.125 µM (40.9 ng/mL) ( Jin et al., 2010 ) and 0.25 µM 
(81.8 ng/mL), respective ly (Ren et al ., 2010 ). In addition, a recent in vitro  study showed that 
niclosamide works as a potent bronchodilator that relaxed histamine induced constriction of mouse 
tracheal rings and human bronchial rings with a half -maximal ef fective concentration (EC 50) of 
124 ng/mL (0.4 µM) and 240 ng/mL (0.7 µM), respectively ( Miner et al., 2019 ). 
PK data available in the literature show significant variability. A single dose of 2000 mg reaches 
maximal systemic serum concentrations in humans of 0.76  μM to 18.3 μM (249  to 5986 ng/mL) 
(Andrews et al., 1982 ). A study with pro state cancer patients  showed that 149 -182 ng/mL (0.46 -
0.56 µM) become available after a single oral dose of 1000  mg (Schweizer et al., 2018 ). These 
studies strongly suggest that the dose regimen foreseen for  clinical developmen t – between 1000 
mg BID, 1000 mg TID and 2000 mg BID - will provide  sufficient systemic and intracellular drug 
levels for effective antiviral and anti -inflammatory  activity. However, there  is a need for well 
characterized PK data to support dose selecti on in COVID -19 and other indications.  
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 21 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 As niclosamide was approved by FDA to treat tapeworms in humans, it has a well -understood  
clinical safety profile on oral administration at 2000 mg daily for up to 7 days. In addition, it has  
been studied in clinical tr ials in oncology and several other indications, and two other Sponsor s 
have recently initiated trials of niclosamide in COVID -19 patients. This Investigational New  Drug 
Application represents the first clinical use of ANA001 capsules, thus there is no prev ious clinical 
data to report for this formulation of niclosamide.  
3.1. Study Rationale  
ANA001 is a new formulation containing 250 mg niclosamide per capsule. Although  other  
niclosamide formulations  have been studied for tapeworm infections and other potential h uman 
uses, limited systemic PK/PD data exists in the literature. To ensure proper systemic levels of 
niclosamide are achieved for therapeutic effect, a SAD/MAD study  with ANA001 capsules  is 
necessary . 
3.2. Background  
Niclosamide has broad in vitro  antiviral activity ( Fan et al., 2019 , Andersen et al., 2019 , Jurgeit et 
al., 2012 , Mazzon et al., 2019 , Xu et al., 2020 , Wu et al., 2004 , Wen et al., 2007 , Gassen et al., 
2019 ) including activity against coronaviruses ( Figure 1). Three initial publications have 
demonstrated that niclosamide inhibited replication of both SARS -CoV at concentrations of 
≥1.56 µM (≥510 ng/mL) ( Wu et al., 2004 ) and 40  µM (13,084 ng/mL)  (Wen et al., 2007 ) and 
Middle East respiratory syndrome (MERS) -CoV with an IC 50 of 0.32 µM (105 ng/mL) ( Gassen et 
al., 2019 ).   
Figure 1 Phylogen etic Tree Showing Antiviral Effects of Niclosamide Against Various 
Virus Families  
 
Source: Adapted from Xu et al 2020.  

CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 22 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 SARS -CoV, MERS -CoV and SARS -CoV -2 share 86% homology ( Wilder -Smith et al., 2020 ) and 
three recent studies have confirmed the in vitro  antiviral efficacy of niclosamide against 
SARSCoV -2. The reported IC 50 values were 0.15 µM (49 ng/mL) ( Shi, 2020, unpublished data), 
0.28 µM (92 ng/mL) ( Jeon et al., 2020 ) and 0 .17 µM (56 ng/mL) ( Gassen et al., 2020 ). 
Furthermore, it was shown that pretreating cells for 24 h with 5 µM (1636 ng/mL) niclosamide 
followed by drug washout and viral infection reduced SARS -CoV -2 replication significantly 
(Gassen et al., 2020 ). This indicates that niclosamide has potential as a prophylactic COVID -19 
treatment and that serum concentrations may not need to continuously exceed in vitro  inhibitory 
levels to be effective.  
3.2.1.  Chemical Nam e/Structure  
USAN:  Niclosamide  
IUPAC:  5 -Chloro -N-(2-chloro -4- nitrophenyl) -2-hydroxybenzamid  
Molecular formula: C 13H8Cl2N2O4 
Molecular weight: 327.1 g/mol  
 
3.2.2.  Nonclinical Studies  
Nonclinical Pharmacology  
In an in vitro  study, Vero E6 cells were infected with a SARS -CoV -2 reporter virus. This virus  has 
a luciferase gene engineered into its genome and when cells are infected with such a reporter  virus, 
they express luciferase that can be quantified to measure viral replic ation. Increasing  
concentrations of niclosamide were added to Vero E6 cells together with reporter SARS -CoV -2. 
Twenty -four hours post -infection, infected cells were assayed for luciferase activity. The antiviral 
IC50 of niclosamide was 0.15 µM (49 ng/mL) ( Shi, 2020, unpublished data).  
In a separate in vitro  study, 50 FDA -approved drugs were screened for their ability to inhibit  
SARS -CoV -2 replication. Vero cells were infected with SARS -CoV -2 in the absence and  presence 
of various drug concentrations. 24 hou rs post infection, cells were scored by  immunofluorescence 
analysis with an antibody specific for the viral N protein of SARS -CoV -2 to generate dose -
response curves for each compound tested. Niclosamide demonstrated an IC 50 of 0.28 µM 
(92 ng/mL). In the same assay, the IC 50 values of remdesivir, chloroquine and  lopinavir were 
11.41  µM (3732 ng/mL), 7.28 µM (2381 ng/mL) and 9.12 µM (2983 ng/mL),  respectively ( Jeon 
et al., 2020 ).  
In an additional in vitro  study, VeroFM cells were in fected with SARS -CoV -2 and treated with  
increasing concentrations of niclosamide. 48 hours post  infection, plaque forming units were  
determined by plaque assay. The antiviral IC 50 of niclosamide was 0.17 µM (56 ng/mL).  

CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 23 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Furthermore, pretreating VeroFM cells  for 24 h with 5 µM niclosamide significantly reduced  viral 
replication ( Gassen et al., 2020 ). 
Nonclinical Toxicology  
Oral toxicology studies for NDA 018669 evaluated niclosamide in mice, rats, rabbits, dogs, and 
cats. Single dose studies included doses as high as 5000 mg/kg in rats without any lethality 
(reviewed in Andrews et al., 1982 ). A rep eat dose study with dogs showed that single oral doses 
of 6000 mg/kg for 8 consecutive days, followed by 4500 mg/kg for another 24 consecutive days 
were tolerated well with no signs of intoxication (reviewed in Andrews et al., 1982). Other repeat 
dose studies in rabbits, cats or dogs with doses that were 2 -5 times the human therapeutic dose and 
lasted 11, 12, and 84 -96 days were non  toxic, based on routine laboratory tests and toxicology. 
Male cats were noted to have a mild reduct ion in white blood cells (WBC), and dogs showed a 
tendency toward watery stools, but otherwise adverse treatment effects were not evident. Other 
studies reported that doses of 250 mg/kg may cause vomiting in dogs and cats. The conclusion of 
these studies w as that niclosamide was a low risk for dosing orally in humans at the standard 
therapeutic regimen of 2000 mg/day (BAYER NDA 018669; Summary Basis for Approval 
(SBA)).  
3.2.3.  Safety  
Between 1971 and 1978, niclosamide was administered to 6365 patients under a US I ND. Doses 
were up to and including 2000 mg/day for 7 days. There were 2385 evaluable patients, of which 
13.3% reported side effects, all of which were mild or moderate, with none requiring treatment 
discontinuation. These included nausea/emesis in 4.1%, ab dominal discomfort/loss of appetite in 
3.4%, diarrhea in 1.6%, drowsiness/dizziness/headache in 1.4%, and skin rash/pruritis in 0.3% of 
patients (NDA 018669 Review Documentation).  
In addition, according to the Safety Review of Niclosamide, Pyrantel, Tricl abendazole and 
Oxamniquine report of the World Health Organization (WHO), there have been 84 reported 
adverse drug reactions related to niclosamide between 1975 and 2004 in the WHO database. They 
include 173 reports from 16 countries and the most common re actions are related to skin and 
appendages (41 reports), gastrointestinal tract (37 reports), cardiovascular system (28 reports) and 
anaphylactic reactions (9 reports).  
Niclosamide was approved as a pregnancy class B drug and is thus safe to use during pre gnancy.  
Summarized below are safety assessment findings reported in the available literature:  
• Prostate cancer patients received 500 mg and 1000 mg of niclosamide orally thrice per day 
for 15 days. TID regimens of >500 mg PO per day suggested the potential  for DLT, 
however these findings are confounded by coadministration of antineoplastic treatment 
associated with a similar range of GI disturbances and occurred after niclosamide was 
dosed for >7 days ( Schweizer et al., 2018 ). 
• Colorectal cancer patients received 2000 mg of niclosamide orally once per day until 
disease progression or toxicity (up to four months). No adverse side effects were reported 
(Burock et al., 2020 ). 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 24 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • 2000 mg niclosamide/person did not result in hematological changes ( Andrews et al ., 
1982 ). 
• No induction of methemoglobinemia was observed in men after oral administration of 30 
mg/kg b.w. (~2000 mg/person) ( Andrews et al., 1982 ). 
• Men and women received 1000 mg niclosamide once or twice per person; children (6 -15 
years of age) received 750 -1000 mg/person; neither scenario resulted in signs of 
intoxication ( Andrews et al., 1982 ). 
• In a Phase I study, adults  were divided into two groups (niclosamide and placebo). Study 
participants received 2000 mg/day for 3 days with a repeat course 6 days later. Transitory 
reactions, such as loose stools and stomach aches were reported ( Andrews et al., 1982 ). 
• No dermal sensitizing effect was observed upon topical administration ( Andrews et al., 
1982 ). 
At the established doses, most adverse events were  transitory and generally mild to moderate.  
3.3. Benefit/Risk Assessment  
Niclosamide is approved for dosing up to 2000 mg PO daily for 7 days. There is limited safety and 
PK data in humans receiving more than 2000 mg as a single dose and/ or more  frequently than once 
daily . The current SAD/MAD study is designed to explore the safety and PK of dosing up to  3000 
mg/day as a single dose and regimens not to exceed  2000 mg /day as divided doses BID or TID.  In 
light of the immediate pressing need for development of an effective an d safe oral therapeutic that 
can prevent progression of COVID -19, the benefit to risk ratio for the study is anticipated to be 
justified.  
More detailed information about the known and expected benefits and risks and reasonably 
expected  adverse events of ANA001  may be found in the Investigator ’s Brochure.  
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 25 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 4. Objectives and Endpoints  
Objectives  Endpoints  
Primary   
• To assess safety and tolerability of 
single oral daily dose s of ANA001 
(1000 mg, 2000 mg and 3000 mg ) 
• To assess safety and tolerability of 
multiple daily oral doses ( twice daily 
[BID] or thrice daily [ TID]) of 
ANA001 for 7 days  • Incidence of adverse events (AEs), 
serious AEs (SAEs), study drug 
discontinuation  due to an AE  (MAD 
portion only), use of concomitant 
medications,  and change from base line 
in clinical laboratory tests, vital signs, 
electrocardiograms (ECG), and 
physical examinations  
Secondary   
• To assess the PK of single and 
multiple doses of ANA001  • AUC 0-t, AUC 0-last, AUC 0-∞ (SAD 
only), Cmax, tmax, t1/2, CL/F, V z/F 
 
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 26 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 5. Study Design  
5.1. Overall  Design  
This is a randomized, double -blind study to be conducted in two parts: single ascending dose 
(SAD) and multiple ascending dose (MAD). Potential participants for each part will undergo 
screening procedures within 30  days of enrolment.  
SAD  
On Day -1, eligible participants will be randomly assigned to active drug or placebo in an 8:2 ratio. 
On Day 1, following an overnight fast of at least 10 hours, participants will receive their assigned 
treatment (1000 mg, 2000 mg, or 3000 mg  of ANA001) with a standardized light meal  (500 to 
750 cal).  A baseline ECG will be performed at  Screening  and at 3 hours after dosing . Blood 
pressure and heart rate will be measured every 8 hours while confined to the clinic. Blood for PK 
will be collecte d before dosing  and at 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h ours after dosing . Participants 
will be discharged on Day 2 following the 24 -hour PK sample and completion of clinical 
laboratory tests and physical examination. They will return on Day 7 (±2) for f ollow -up procedures 
including physical examination, laboratory tests, and assessment of AEs and concomitant 
medication use.  
MAD  
On Day -1, eligible participants will be randomly assigned to active drug or placebo in a 9:3 ratio 
on a BID (q12h) or TID (q8h)  schedule, to be determined based on the PK results of the SAD 
cohorts . Total daily doses will not exceed  2000 mg of ANA001 . On Days 1 through 7, participants 
will receive their assigned treatment in the morning with a standardized light meal  (500 to 750 c al) 
following an overnight fast of at least 10 hours. Afternoon or evening doses will be given with a 
light snack .  A baseline ECG will be performed at Screening and at 3 hours after the second dose 
on Day 7. Blood  pressure and heart rate will be measured every 8 hours while confined to the 
clinic.  
During BID dosing, blood for PK will be collected on Days 1 and 7  before dosing   and at 0.5, 1, 
2, 4, 6, 8, 10, and 12 hours after dosing . Blood samples will also be collected on Days 2, 4, 6, and 
8 before dosin g and before the 12 hour dose on Days 2, 4, and 6.  
During TID dosing, blood for PK will be collected on Days 1 and 7 before dosing  and at 0.5, 1, 2, 
4, 6, and 8 hours after dosing . Blood samples will also be collected on Days 2, 4, 6, and 8 before 
dosing , before the 8 hour dose on Days 2, 4, and 6, and before the 16 hour dose on Day 6.  
Participants will be discharged on Day 8 following the last PK sample and completion of clinical 
laboratory tests and physical examination. They will return on Day 15 (±2) for follow -up 
procedures including physical examination, laboratory tests, and assessment of AEs and 
concomitant medication use.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 27 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 5.2. Participant and Study Completion  
A minimum of 30 par ticipants will be enrolled in the SAD part and up to 36 participants in the 
MAD part. At least 3 participants of each sex will be included in each cohort.  
5.3. End of Study  Definition  
A participant is considered to have completed the study if he/she has complet ed all phases of the 
study including the last scheduled procedure show n in the Schedule of Activities.  
The end of the study is defined as the date of the last visit of the last participant in the study.  
5.4. Scientific Rationale for  Study Design  
Sequential timi ng of the ascending dose cohorts will allow early stopping if serious or 
unanticipated safety signals are observed at any dose level.  
5.5. Justification for Dose  
Niclosamide was approved by FDA to treat tapeworms in humans and has a well  understood 
clinical saf ety profile with oral administration at 2000 mg daily for up to 7 days. Furthermore, a 
single dose of 2000 mg reaches maximal systemic serum concentrations in humans of 0.76 μM to 
18.3 μM (249 ng/mL to 5986 ng/mL) ( Andrews et al. , 1982 ). A study with prostate cancer patients 
showed that 149  ng/mL to 182 ng/mL (0.46  µM to 0.56 µM) become available after a single oral 
dose of 1000 mg ( Schweizer et al., 2018 ). In a very recent study, colorectal cancer patients received 
2000 mg of niclosamide orally once a day until disease progression or toxicity (up to four months). 
Plasma levels mainly peaked 240 minutes after the first niclosamide administration with a median 
Cmax of 2.03 µM (665 ng/mL) ( Burock et al., 2020 ). The lower bounds of the reported C max values 
fall within the effective in vitro ranges of niclosamide as an antiviral agent (0.15 -0.28 µM, 49 -92 
ng/mL) (Shi, 2020, unpublished results; Jeon et al ., 2020 , Gassen et al ., 2020 ) and an anti -
inflammatory drug that inhibits NF -kB and STAT3 at 0.13 µM (42.5 ng/mL) ( Jin et al., 2010 ) and 
0.25 µM (81.8 ng/mL) ( Ren et al., 2010 ), respectively.  
These studies strongly suggest that the dose regimens between 1000 mg BID to 2000 mg BID or 
1000 mg TID to 1500 mg TID will provide sufficient systemic and intracellular drug levels for 
effective antiviral and anti -inflammatory activity. The current study is designed to assess the safety 
of single doses of niclosamide up to  3000 mg and multiple dosing regimens not to exceed  2000 
mg daily divided BID or TID . The PK data from this study will be used to refine  the optimum dose 
and frequency of administration to achieve antiviral and anti -inflammatory activity in humans.  
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 28 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 6. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exempti ons, is not permitted.  
6.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Signed the COVID and study  informed consent form s as described in Appendix 3  which  
includes compliance with the requirements and restrictions listed in the informed consent 
form (ICF) and in this protocol  
2. Man or woman, 18 to 65 years of age inclusive at the time of signing the informed 
consent form  
3. Overtly healthy as determined by medical evaluation including medical history, physical 
examination, clinical laboratory tests  
4. Body mass index (BMI) within 18 to 30.0 kg/m2 (inclusive) and body weight not less 
than 50 kg  
5. Blood pressure (after supine for 5 minutes)  at Screening and Day -1 between 90 and 140 
mmHg systolic, inclusive, and no higher than 90 mmHg diastolic.  
6. A 12 -lead electrocardiogram (ECG) at Screening consistent with normal cardiac 
conduction and function, including:  
• Sinus rhythm  
• Pulse rate between 50 and 100 beats per minute (bpm)  
• QTc interval  450 milliseconds (QT interval corrected using Fridericia correction 
method [QTcF])  
• QRS interval of <120 milliseconds  
• PR interval <200 milliseconds  
• Morphology consistent with healthy cardiac conduction and funct ion 
7. Non-smoker or ex -smoker for >12 months  
8. If male, must agree to use contraception as detailed in Appendix 5  of this protocol during 
the treatment period and for at least 30 days (a spermatogenesis cycle) after the last dose 
of study treatment and refrain from donating sperm during this period  
9. If female, is not pregnant (see Appendix 5), not breastfeeding , and meets at least one of 
the following conditions:  
Not a woman of childbearing potential (WOCBP) as defined in Appendix 5  
OR 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 29 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during 
the treatment period and for at least 30 days  (one menstrual cycle)  after the last 
dose of study treatmen t. 
Note: Retesting of abnormal lab oratory  values that may lead to exclusion will be allowed once. 
Retesting will take place during an unscheduled visit in the screening phase.  
6.2. Exclusion Criteria   
Participants are excluded from the study if any of the follo wing criteria apply:  
1. Has a history of or current clinically significant medical illness including but not limited 
to: cardiac arrhythmias or other cardiac disease; hematologic disease; coagulation 
disorders (including any abnormal bleeding or blood dyscrasias); lipid abnormalities; 
significant pulmonary disease, including bronchospastic respiratory disease; diabetes 
mellitus; hepatic or renal insufficiency (creatinine clearance below 60 mL/min); thyroid 
disease; neurologic or psychiatric disease; infection; or any other illness that the 
Investigator  considers should exclude the subject or that could interfere with the 
interpretation of the study results . 
2. Has known allergy to niclosamide or salicylate -containing medications.  
3. Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at 
screening as assessed per Appendix 6  
4. Clinically significant abnormal physical examination, vital signs or 12 lead ECG at 
screening as deemed appropriate by the Investigator  
5. Has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive 
for HIV ; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody 
(anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg 
or anti -HCV at Screening . 
6. History of drug or alcohol abuse according to Diagnostic and Statistical Man ual of 
Mental Disorders (4th edition) criteria within 5 years before screening or positive test 
result(s) for alcohol and/or drugs of abuse  at screening and admission  
7. Has received an investigational drug or used an invasive investigational medical device 
within 1 month or within a period less than 10 times the drug’s half -life, whichever is 
longer, before Day 1.  
8. Has preplanned surgery or procedures that would interfere with the conduct of the study  
9. Is an employee of the Investigator  or study site, with dire ct involvement in the proposed 
study or other studies under the direction of that Investigator  or study site, as well as 
family members of the employees or the Investigator  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 30 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 6.3. Lifestyle Restrictions  
6.3.1.  Meals and Dietary Restrictions  
1. Participants will r efrain fro m consumption of red wine, Seville oranges, grapefruit or 
grapefruit juice , pomelos, exotic citrus fruits, grapefruit hybrids , or fruit juices  from 3 
days before the start of study treatment  until after the final dose . 
6.3.2.  Caffeine, Alcohol, and Tobacco  
1. Participant s will abstain from ingesting caffeine - or xanthine -containing products ( e.g., 
coffee, tea, cola drinks , and chocolate) for 24 hours before  the start of dosing until after 
collection o f the final pharmacokinetic ( PK) blood sample . 
2. Participant s will abstain from alcohol for 24 hours before  the start of dosing until after 
collection o f the final PK blood sample .  
3. Use of tobacco products will not be allowed during the study . 
6.3.3.  Activity  
1. Participant s will abstain from strenuous exercise for  24 hours before each blood collection 
for clinical laboratory tests.  Participant s may participate in light recreational activities 
during studies ( e.g., watch ing television, read ing). 
6.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study  but are 
not subsequently entered in to the study . A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure particip ants to meet the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any serious adve rse event  (SAE) . 
Individuals who do not meet the criteria for participation in this study (screen failure) may not  be 
rescreened . 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 31 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 7. Treatment s 
Study treatment is defined as an y investigational treatment(s), marketed product(s), placebo , or 
medical device (s) intended to be administered to a study participant according to the study 
protocol.  
7.1. Treatment s Administered  
Study Treatment Name:  ANA001  Placebo  
Dosage formulation:  Size 0 capsule  Size 0 capsule  
Unit dose strength(s)/  
Dosage level(s):  250 mg/capsule  NA 
Route of Administration   oral oral 
Dosing instructions:  
 4, 6, 8, or 12 capsules 
with light meal or snacka 4, 6, 8, or 12 capsules 
with light meal or snacka 
Packaging and Labeling  Bulk bottle   
Storage conditions  Capsules (ANA001 or matching placebo) should be 
stored at controlled room temperature  (20-25 °C) out 
of direct sunlight.  
Manufacturer  ANA Therapeutics, Inc.  
a 500 to 750 cal  
7.2. Dose Modification  
The dose(s) and schedule (BID or TID) in the MAD part will be determined following review of 
the safety and PK data from the SAD part. Total daily doses will no t exceed  2000 mg. 
7.3. Method of Treatment Assignment  
Within each cohort, participants will be random ly assigned to active drug or placebo as they qualify 
for the study using a computer -generated randomization.  
7.4. Blinding  
Participants will be randomly assigned to receive study treatment. Investigator s will remain 
blinded to each participant’s assigned study treatment throughout the course of the study. In order 
to maintain this blind, an otherwise uninvolved 3rd party (e.g., site pharmacist) will be responsible 
for the dispensation of all study treatm ent and will endeavor to ensure that there are no differences 
in time taken to dispense following randomization.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 32 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 7.5. Preparation/Handling/Storage /Accountability  
The Investigator  or designee  must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment  received and any discrepancies are reported and 
resolved before  use of the study treatment . 
Only participant s enrolled in the study may receive stud y treatment and only authorized site staff 
may supply or administer study treatment.  All study treatments must be stored in a secure , 
environmentally controlled , and monitored (manual or automated) area in accordance with the 
labeled  storage conditions wit h access limited to the Investigator  and authorized site staff . 
The Investigator , institution, or the head of the medical institution (where applicable) is responsible 
for study treatment accountability, reconciliation, and record maintenance (i .e., receipt, 
reconciliation , and final disposition records) . 
7.6. Treatment Compliance  
Participants will receive study treatment under the direct supervision of the Investigator  or 
designee. A hand - and mouth check will be done to ensure that the participants swal lowed the 
drugs.  
7.7. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins , 
and/or herbal supplements) that the participant  is receiving at the time of enrollment  or receives 
during the study  must be reco rded along with : 
• Reason for use  
• Dates of administration including start and end dates  
• Dosage informati on including dose and frequency  
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.  
Participant s must abstain from taking prescription or nonprescription drugs (including vitamins 
and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme 
inducer) or 5 half -lives (whichever is longer) before  the start of study treatment  until completion 
of the follow -up visit, unless , in the opinion of the Investigator  and Sponsor , the medication will 
not interfere with the study.  
Acetaminophen , at doses of   2 grams/day , is permitted for use any time during the study . Other 
conco mitant medication may be considered on a case -by-case basis by the Investigator . 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 33 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 7.7.1.  Rescue Medicine  
No rescue medication will be provided.  
7.8. Treatment after the End of the Study  
Participants will not receive study drug (ANA001 or matching placebo) after the end of the 
study.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 34 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 8. Discontinuation/Withdrawal Criteria   
8.1. Discontinuation of Study Treatment   
An un expected AE related to study drug could lead to temporary or permanent discontinuation of 
a participant’s study treatment , as determined by the Medical Monitor or Investigator .   
8.2. Withdrawal from the Study  
A participant  may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the Investigator  for safety, behavioral , compliance, or 
administrative reasons . 
If the participant  withdraws consent  for disclos ure of fut ure information, the Sponsor  may retain 
and continue to use any data collected before such a withdrawal of consent . 
If a participant  withdraws from the study, he/she may request destruction of any samples taken 
and not tested , and the Investigator  must doc ument this in the site study records . 
See SoA (Section 2) for data to be collected at the time of study  discontinuation and follow -up 
and for any fu rther evaluations that need to  be completed . 
Participants who withdraw will not be replaced.  
8.3. Lost to Follow Up  
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.   
The following actions must be taken if a participant  fails to return to  the clinic for a required 
study visit:  
• The site must attempt to contact the participant  and reschedule the m issed visit as soon as 
possible and counsel th e participant  on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant  wishes to and/or should continue in 
the study.  
• Before a  participant  is deemed lost to follow up, the Investigator  or designee must make 
every effort to regain contact with the participant  (where possible, 3 telephone calls and , 
if necessary , a certified letter to the participant ’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the participant ’s 
medical record . 
• Should the participant  continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to f ollow -up.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 35 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 9. Study Assessments  and Procedures  
• Study procedures and their timing are summarized in the SoA.  Protocol waiver s or 
exemptions are not allowed.  
• Immediate  safety concerns  should be discussed with the Sponsor  immediatel y upon 
occurrence or awareness to determine if the participant should continue or discontinue study 
treatment . 
• Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.  
• All screening eval uations must be completed and reviewed to confirm that  potential 
participant s meet all eligibility criteria. The Investigator  will maintain a screening log to 
record details of all participant s screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (e.g., blood 
count)  and obtained before signing of the ICF  may be utilized for scre ening or baseline 
purposes provided the procedure s met the protocol -specified  criteria and were  performed 
within the time  frame defined in the SoA . 
Volume of Blood to be Collected From Each Subject  - SAD  
Type of Sample  Volume per Sample  
(mL)  No. of Samples / 
Subject  Total Volume 
of Blood  
(mL)a 
Safety (including screening 
and post treatment 
assessments)     
- Hematology  4 4 16 
- Serum chemistry  8.5 4 34 
serology (HIV, hepatitis) 8.5 1 8.5 
serum -hCG pregnancy 
test 3 1 3 
Pharmacokinetic samples  - 
SAD  4 10 40 
Total  – SAD    101.5 
a Calculated as number of samples multiplied  by amount of blood per sample.  
  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 36 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
  
Volume of Blood to be Collected From Each Subject  - MAD  
Type of Sample  Volume per Sample  
(mL)  No. of Samples / 
Subject  Total Volume 
of Blood  
(mL)a 
Safety (including screening 
and post treatment 
assessments)     
- Hematology  4 6 64 
- Serum chemistry  8.5 6 51 
serology (HIV, hepatitis) 8.5 1 8.5 
serum -hCG pregnancy 
test 3 1 3 
Pharmacokinetic samples  – 
MAD (BID/TID)  4 25/28  100/112  
Total – BID 
Total - TID   226.5  
238.5  
a Calculated as number of samples multiplied  by amount of blood per sample.  
Approximately 102 mL of blood will be collected during the SAD part. During the MAD, 
approximately 22 7 mL will be collected following BID dosing and 2 39 mL during TID dosing.  
9.1. Safety  Assessments   
Safety assessments include incidence and frequency of AEs/SAEs, study drug discontinuation 
due to an AE (MAD portion only), use of concomitant med ications, and changes from baseline 
in clinical laboratory tests, vital signs, electrocardiograms (ECG), and physical examinations . 
9.1.1.  Physical Examinations  
A complete physical examination , conducted at screening,  will include, at a minimum, 
assessments of th e Skin, Cardiovascular, Respiratory, Gastrointestinal , and Neurological 
systems. Height and weight will also be measured and recorded.  
A brief physical examination will include, at a minimum, assessments of the  Cardiovascular, 
Respiratory, Gastrointestinal  systems.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 37 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 9.1.2.  Vital Signs  
Vital signs should be taken in a quiet setting without distractions (e .g., television, cell phones) 
and before any blood collections.  
Oral temperature, pulse rate, respiratory rate, and blood pressure will be assessed.  
Blood pressure and pulse measurements will be assessed with a completely automated device  
after 3 to 5 minutes rest in a supine position . Manual techniques will be used only if an 
automated device is not available.  
Blood pressure and pulse measurements will be m easured after 3 to 5 minutes rest in a supine 
position.  
9.1.3.  Electrocardiogram s 
A single ECG will be obtained for screening and at 3 hours after dosing during the SAD po rtion 
of the study and at Screening and 3 hours after dosing  on Day 7 during the MAD portion . An ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals  
will be used . 
9.1.4.  Clinical Safety Laboratory Assessments  
See Appendix 2  for the list of clinical laboratory tests to be performed and the SoA (Section 2) for 
the timing and frequency.  
The Investigator  must review the laboratory report, document this review, and record any clinically 
relevant changes (as per the reference laboratory values [Appendix 6 ]) occurring during the study 
in the AE section of the CRF. The laboratory reports must be filed with the source documents. 
Clinically significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by the Investigator  to be more severe than expected for the 
participant's condition.  
All labo ratory tests with values considered clinically significantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant as per the reference laboratory valu es in Appendix 6 . 
• If such values do not return to normal/baseline within a period of time judged reasonable 
by the Investigator , the etiology should be identified and the Sponsor  notified.  
• All protocol -required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the SoA.   
• If laboratory values from non -protocol specified laboratory assessments performed at the 
institution’s local labora tory require a change in participant management or are considered 
clinically significant as given in Appendix 6  (e.g., SAE or AE or dose modification), then 
the results must be recorded in the CRF.   
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 38 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 9.2. Adverse Events  
The definiti ons of an AE or SAE can be found in Appendix  4. 
AE will be reported by the participant  (or, when appropriate, by a caregiver, surrogate, or the 
participant 's legally authorized  representative) .  
The Investigator  and any designees are responsible for detecting, documenting, and recording  
events that meet the definition of an AE or SAE and remain responsible for following up  AEs that 
are serious, considered related to the study treatment or study  procedures , or tha t caused the 
participant to discontin ue the  study .  
9.2.1.  Time Period and Frequency for Collecting AE and SAE Information   
All AE s and SAEs will be collected from the signing of the ICF  until the follow -up visit  at the 
time points specified in the SoA ( Section 2). 
Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the Medical History/Current Medical Conditions section of the case 
report f orm (CRF ) not the AE section . 
All SAE s will be recorded and reported to the Sponsor  or designee  within 24 hours, as indicated 
in Appendix  4. The Investigator  will submit any updated SAE data to the Sponsor  within 24  hours 
of it being available.  
Investigator s are no t obligated to actively seek AE s or SAE s in former study participant s. However, 
if the Investigator  learns of any SAE, including a death, at any time after a participant  has been 
discharged from the study, and he/she considers the event to be reasonably related to the study 
treatment or study participation, the Investigato r must promptly notify the Sponsor . 
The method of recording, evaluating , and assessing causality of AE s and SAE s and the procedures 
for completing and transmitting SAE reports are provided in  Appendix 4. 
9.2.2.  Method of Detecting AE s and SAE s 
Care will be taken not to introduce bias when detecting AE s and/or SAEs . Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrence s.  
9.2.3.  Follow -up of AE s and SAE s 
After the initial AE/SAE report, the Investigator  is required to proactively follow each participant 
at subsequent visits/contacts. All SAE s will be followed until resolution, stabiliz ation , the event is 
otherwise explained, or the participant is lost to follow -up (as defined in Section 8.3). Further 
information on follow -up procedures is given in Appendix 4 . 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 39 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 9.2.4.  Regulatory Reporting Requirements for SAE s 
Prompt notification by the Investigator  to the Sponsor  of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participant s and the safety of a study 
treatment under clinical investigation are met.  
The Sponsor  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The Sponsor  
will comply with country -specific regulatory requirements relating to safe ty reporting to the 
regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) , 
and Investigator s. 
Investigator  safety reports must be prepared for suspected unexpected serious adverse reactions  
(SUSAR)  according to local regulatory requirements and Sponsor  policy and forwarded to 
Investigator s as necessary.  
An Investigator  who receives an Investigator  safety report describing a SAE or other specific safety 
information ( e.g., summary or listing of SAE s) from the Sponsor  will review and then file it along 
with the Investigator ’s Brochure  and will notify the IRB/IEC, if appropriate according to local 
requirements . 
9.2.5.  Pregnancy  
Details of all pregnancies in female participant s and , if indicated , female partners of male 
participant s will be collected after the start of study treatment and until 30 days after the last dose.  
If a pregnancy is reported, the Investigator  should inform the Sponsor  within 24 hours of learning 
of the pregnancy and should  follow the procedures outlined in Appendix 5 . 
Abnormal pregnancy outcomes (e .g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
9.3. Stopping Rules in Response to SAE s or Other Events  
Dose -limiting toxicity AEs will be defined as Grade ≥3, treatment -emergent, treatment -related 
laboratory abnormalities (Appendix 6) or AEs per the grading system  by US Department of 
Health and Human Services  (CTCAE, Version 5.0) The following Stopping Criteria will be used:  
Clinical Findings:  
1. Anaphylaxis or Grade ≥3 skin rash or pruritis  
2. Grade ≥3 nausea, emesis or diarrhea  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 40 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Laboratory Findings:  
1. Evidence of new onset of acute renal or hepatic failure, defined by increases in 
BUN, creatinine, or LFTs (AST, ALT, Alkaline phosphatase) that reflect new 
evidence of Grade 3 thresholds for liver function tests, for creatinine, and for 
electrolytes attrib utable to the administration of drug in the context of the 
Investigator’s evaluation.  
2. Evidence of acute infection or inflammation, defined by changes in the WBC and 
differential, attributable to the administration of drug in the context of the 
Investigato r’s evaluation.  
3. Any “unexpected” Grade ≥3 laboratory test result.  
If one of the above clinical or laboratory criteria for stopping occurs in any subject, further 
study recruitment and subject dosing will be halted  until a full safety assessment can be 
completed . Unblinding of the affected subject will be performed and the PI and Sponsor will 
review the totality of clinical data and any other circumstances possibly related to the “Stopping 
Criteria” findings  to determine if the study can be resumed, modifi ed, or will be permanently 
terminated .  
9.4. Treatment of Overdose  
For this study, any dose of ANA001 greater than 3000  mg within a 24-hour time period will be 
considered an overdose.  
In the event of an overdose , the Investigator  should:  
1. Contact the Medical Monitor immediately . 
2. Closely monitor the participant  for any AE/SAE  and laboratory abnormalities until 
ANA001  can no longer be detected systemically (at least 7 days). 
3. Document the quantity of the excess dose as well as  the duration of the overdose  in the 
CRF.  
Decisions regarding dose interruptions or modifications will be made by the Investigator  in 
consultation with  the Medical Monitor based on the clinical evaluation of the participant . 
9.5. Pharmacokinetics  
Whole blood sa mples of approximately 4 mL will be collected for measurement of plasma  
concentrations of ANA001 as specified in the SoA (Section 2).  Additional  samples may be 
collected during the study if warranted and agreed upon between the Investigator  and the Sponsor . 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 41 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Instructions for the collection and handling of biological samples will be provided by the Sponsor . 
The actual date and time (24 -hour clock ti me) of each sample will be recorded . 
Any changes in the timing or addition of time  points for any planned study assessments must be 
documented and approved by the relevant study team member and then archived in the Sponsor  
and site study files, but will no t constitute a protocol amendment. The IRB/IEC will be informed 
of any safety issues that require alteration of the safety monitoring scheme or amendment of the 
ICF. 
The following PK parameters for ANA001  will be estimated using actual sample collection 
times:  
Cmax maximum plasma concentration during a dosing interval  
Cmin minimum plasma concentration during a dosing interval  
tmax time to reach the maximum plasma concentration  
AUC t area under the plasma concentration -time curve from time 0 to time t  after dosing  
AUC 0-last area under the plasma concentration -time curve from time 0 to time the last 
quantifiable concentration  
AUC 0-∞ area under the plasma concentration -time curve from time 0 to  infinity  
t1/2 elimination half -life associated with the terminal slope ( z) of the 
semilogarithmic drug concentration -time curve, calculated as 0.693/ z 
CL/F  Systemic clearance  
Vz/F Volume of distribution  
 
9.6. Medical Resource Utilization and Health Economic s 
Not applicable.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 42 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 10. Statistical Considerations  
10.1. Sample Size Determination   
Sample size was not based on statistical considerations.  
10.2. Populations for Analyses  
For purposes  of analysis, the following populations are defined:  
Population  Description  
Enrolled  All participants who sign the ICF  
Safety  All participants randomly assigned to study treatment and who 
take at least 1 dose of study treatment. Participants will be 
analyzed according to the treatment they actually received.  
Pharmacokinetic  All participants randomly assigned to study treatment, who take 
at least 1 dose of study treatment , and contribute at least 1 post -
dose evaluable PK sample . Participants will be analyzed 
according to the dose they actually received.  
10.3. Statistical Analyses  
The statistical analysis plan will be developed and finalized before database lock and will describe 
the participant populations  to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. This section  is a summary  of the planned statistical analyses 
of the primary and secondary endpoints . 
10.3.1.  Safety Analyses  
All safety analyses will be performed on the Safety Population. Safety parameters will include 
frequency of treatment -emergent AEs (TEAEs), SAEs, study drug discon tinuation due to an AE 
(MAD portion only), concomitant medication use, and changes from baseline in clinical laboratory 
results, vital signs, ECG, and physical examinations. TEAEs are defined as AEs that started or 
worsened after dosing. Adverse events wil l be coded using the latest version of the Medical 
Dictionary for Regulatory Activities. A list of participants who have SAEs and who discontinue 
from the study due to an AE will be provided. Treatment -emergent AEs will be summarized by 
system organ class and preferred term for each dose level.  
Individual results of laboratory tests (chemistry, hematology, and urinalysis) will be listed and 
summarized. Baseline, post -dose, and change from baseline to post -dose laboratory data will be 
summarized by dose. Ind ividual results of vital signs will be listed and summarized. Observed 
values and changes from baseline in vital signs will be summarized by dose. Individual results of 
ECG parameters from the 12 -lead safety ECGs will be listed and changes from baseline wi ll be 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 43 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 summarized by dose. Physical examination findings and concomitant medication use will be 
presented in data listings.   
10.3.2.  Pharmacokinetic  Analyses  
The non-compartmental PK analyses will be described in the Statistical Analysis Plan finalized 
before  database lock. Plasma concentrations of ANA001 will be summarized by dose over each 
scheduled sampling time using descriptive statistics. Individual plasma concentration data versus 
actual time points will be presented in listings. Pharmacokinetic parameters o f ANA001 will be 
summarized by dose using descriptive statistics. Individual PK parameters will be presented in a 
data listing. Dose proportionality will be assessed graphically and using the power model.  
10.3.3.  Interim Analyses   
Data from the SAD Cohorts S1 through S3 will be summarized and evaluated to determine the 
doses and schedule to be used in a potential 4th SAD cohort and the BID and TID  MAD cohorts. 
The Statistical Analysis Plan will describe the planned interim analyses  in greater detail . 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 44 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 11. Reference s 
Abrams G. J. et al. The treatment of human tapeworm infections with 'Yomesan'. S Afr Med J.  
(1963). PMID: 14010769  
 
Ai, N. et al. Niclosamide is a Negative Allosteric Modulator of Group I Metabotropic Glutamate  
Receptors: Implications for Neuropathic Pa in. Pharm Res.  (2016). doi: 10.1007/s11095 -
0162027 -9 
 
Andersen, P. I. et al. Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and  
homoharringtonine. Viruses  (2019). doi:10.3390/v11100964  
 
Andrews, P. et al. The biology and toxicol ogy of molluscicides, bayluscide, Pharmacol. Ther.  
(1982). doi: 10.1016/0163 -7258(82)90064 -x  
 
Beigel, J. H. et al. Remdesivir for the Treatment of Covid -19 — Preliminary Report. NEJM . 
(2020) doi:10.1056/NEJMoa2007764  
 
Beristain -Castillo, E. et al. CYP1A1 and Cnr nitroreductase bioactivated niclosamide in vitro.  
Mutagenesis . (2013). doi: 10.1093/mutage/get043  
 
Burock, S. et al. Phase II trial to investigate the safety and efficacy of orally applied niclosamide  
in patients with metachronous or sychro nous metastases of a colorectal cancer progressing after  
therapy: the NIKOLO trial. BMC Cancer . (2018). doi: 10.1186/s12885 -018-4197 -9  
 
Burock, S. et al. Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential  
anticancer drug in a patient cohort of the NIKOLO trial. J. Clin. Oncol . (2020). 
doi:10.1200/jco.2018.36.15_suppl.e14536 - (abstract only)  
 
Cerles, O. et al. Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal  
Cancer Therapeutic Respo nse. Mol Cancer Ther . (2017). doi: 10.1158/1535 -7163  
 
Chang, Y. W. et al. Pharmacokinetics of anti -SARS -CoV agent niclosamide and its analogs in  
rats. J. Food Drug Anal . (2006). ISSN: 1021 -9498  
 
Chen, W. et al. Niclosamide: Beyond an antihelminthic drug.  Cell Signal . (2018). 
doi:10.1016/j.cellsig.2017.04.001  
 
Cil, O. et al. Slowed gastric emptying and improved oral glucose tolerance produced by a  
nanomolar -potency inhibitor of calcium -activated chloride channel TMEM16A. FASEB J . 
(2019). doi:10.1096/fj.20 1900858R  
 
Cortinas de Nava, C. et al. Mutagenicity of antiamebic and anthelmintic drugs in the Salmonella  
typhimurium microsomal test system. Mutat Res . (1983). doi: 10.1016/0165 -1218(83)90155 -6.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 45 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Espinosa -Aguirre, J. J. et al. Mutagenic activity of 2-chloro -4-nitroaniline and 5 -chlorosalicylic  
acid in Salmonella typhimurium: two possible metabolites of niclosamide. Mutat Res . (1991).  
doi: 10.1016/0165 -7992(91)90131 -m 
 
Fan, X. et al. Contributions of Hepatic and Intestinal Metabolism to the Dispositio n of 
Niclosamide, a Repurposed Drug with Poor Bioavailability. Drug Metab Dispos.  (2019). 
doi:10.1124/dmd.119.086678   
 
Fan, X. Z. et al. Dual activity of niclosamide to suppress replication of integrated HIV -1 and  
Mycobacterium tuberculosis (Beijing). Tuberculosis  (2019). doi: 10.1016/j.tube.2019.04.008  
 
Gassen, N. C. et al. SKP2 attenuates autophagy through Beclin1 -ubiquitination and its inhibition  
reduces MERS -Coronavirus infection. Nat. Commun . (2019). doi:10.1038/s41467 -019-13659 -4  
 
Gassen, N. C. et al. Analysis of SARS -CoV -2-controlled autophagy reveals spermidine, 
MK2206,  and niclosamide as putative antiviral therapeutics. bioRxiv preprint . (2020). 
doi:10.1101/2020.04.15.997254  
 
Giri, A. K. et al. Comparative genotoxicity of six salicylic acid deri vatives in bone marrow cells  
of mice. Mutat Res . (1996). doi: 10.1016/s0165 -1218(96)90121 -4  
 
Hecht G. and C. Gloxhuber, “Experimentelle Untersuchungen mit N -(2’-Chlor -4’-nitrophenyl)5 -
chlor -salicylamid,  einem  neuen  Bandwurmmittel.”,/Experimental  Studies  on N-(2’-chloro -
4’nitrophenyl) -5-chlorosalicylamide,  a New Taeniacide . 2. Mitteilung: Toxikologische  
Untersuchungen. Arzneimittel -Forsch.  (1960). 10: 881 -890 (German / translated version)  
 
Hirano T. and Murakami M. COVID -19: A New Virus, but a Familiar Receptor and Cytokine  
Release Syndrome. Immunity . (2020). doi: 10.1016/j.immuni.2020.04.003  
 
Jeon, S. et al. Identification of antiviral drug candidates against SARS -CoV -2 from 
FDAapproved  drugs.  Antimicrob  Agents  Chemother.  (2020).  doi:10.1128/A AC.00819 -20 
 
Jin, Y. et al. Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem  
Cells: Inactivation of the NF -κB Pathway and Generation of Reactive Oxygen Species. Cancer  
Res. (2010). doi: 10.1158/0008 -5472.CAN -09-3950  
 
Jones, W. E . Niclosamide as a treatment for Hymenolepis diminuta  and Dipylidium caninum  
infection in man. Am. I.Trop.Med. Hyg . (1979). doi: 10.4269/ajtmh.1979.28.300  
 
Jurgeit, A. et al. Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad  
Antivira l Effects. PLoS Pathog . (2012). doi: 10.1371/journal.ppat.1002976  
 
Li, S. L. et al. Niclosamide ethanolamine inhibits artery constriction. Pharmacol Res . (2017).  
doi: 10.1016/j.phrs.2016.11.008  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 46 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
  
Lin, C. K. et al. Preclinical evaluation of a nanoformulate d antihelminthic, niclosamide, in  
ovarian cancer. Oncotarget . (2016). doi: 10.18632/oncotarget.7113  
 
Lodagekar, A. et al. Formulation and evaluation of cyclodextrin complexes for improved  
anticancer activity of repurposed drug: Niclosamide. Carbohydr Polym.  (2019). 
doi:10.1016/j.carbpol.2019.02.041  
 
Lu, D. et al. Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and  
UDP -glucuronosyltransferases: metabolite elucidat ion and main contributions from CYP1A2 and  
UGT1A1. Xenobiotica.  (2015). doi: 10.3109/00498254.2015.1047812  
 
Mazzon, M. et al. Identification of broad -spectrum antiviral compounds by targeting viral entry.  
Viruses  (2019). doi:10.3390/v11020176  
 
Mehra, M. R . et al. Hydroxychloroquine or chloroquine with or without a macrolide for  
treatment of COVID -19: a multinational registry analysis. Lancet . (2020). doi: 
10.1016/S01406736(20)31180 -6 
 
Miner, K. et al. Drug repurposing: The anthelmintics niclosamide and nit azoxanide are potent  
TMEM16A antagonists that fully bronchodilate airways. Front. Pharmacol.  (2019) 
doi:10.3389/fphar.2019.00051  
 
Nair, A. B and S. A. Jacob. A simple practice guide for dose conversion between animals and  
human. J Basic Clin Pharma . (2016 ). doi: 10.4103/0976 -0105.177703 NDA 018669 Review 
Documentation  
 
Osada, T. et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits  
antitumor responses in tumors with activating APC mutations. Cancer Res.  (2011). 
doi:10.1158/0008 -5472  
 
Ostrosky -Wegman, P. et al. Susceptibility to genotoxic effects of niclosamide in human  
peripheral lymphocytes exposed in vitro and in vivo. Mutat. Res.  Lett. (1986). 
doi:10.1016/01657992(86)90015 -1 
 
Park, D. W. et al. Role of JAK2 –STAT3 in TLR2 -Mediated Tissue Factor Expression. J Cell  
Biochem . (2013). doi: 10.1002/jcb.24472  
 
Perera, D. R. et al. Niclosamide treatment of cestodiasis. Clinical trials in the United States. Am J  
Trop Med Hyg . (1970). doi: 10.4269/ajtmh.1970.19.610  
 
Rehman, M. U. et al. Fabrication of Niclosamide loaded solid lipid nanoparticles: in vitro  
characterization and compar ative in vivo evaluation. Artif. Cells, Nanomedicine Biotechnol . 
(2018). doi:10.1080/21691401.2017.1396996  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 47 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Ren, X. et al. Identification of Niclosamide as a New Small -Molecule Inhibitor of the STAT3  
Signaling Pathway. ACS Med Chem Lett . (2010). doi: 10.10 21/ml100146z  
 
Schuringa, J. J. et al. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid  
leukemia cells caused by the autocrine secretion of interleukin -6. Blood . (2000). 
PMID:10845908   
 
Schweizer, M. T. et al. A phase I study of nic losamide in combination with enzalutamide in men  
with castration -resistant prostate cancer. PLoS One . (2018). doi: 10.1371/journal.pone.0198389  
 
Silva Borba, M. G. et al. Chloroquine diphosphate in two different dosages as adjunctive therapy  
of hospitaliz ed patients with severe respiratory syndrome in the context of coronavirus 
(SARSCoV -2) infection:  Preliminary  safety  results  of a randomized,  double -blinded,  phase  IIb 
clinical  trial (CloroCovid -19 Study).  medRxiv  preprint . (2020).  
doi:10.1101/2020.04.07.20056424  
 
Strufe, R. and Goennert, R. Experimentelle Untersuchungen mit N -(2'-Chlor -4'-nitrophenyl) -
5chlorsalicylamid,  einem neuen Bandwurmmittel. / Experimental Studies on N -(2’-chloro -
4’nitrophenyl) -5-chlorosalicylamide,  a New Taen iacide . Arzneimittel -Forsch . (1960) 10: 881 -
884 (German / translated version)  
 
US Departme nt of Health and Human Services. Common Terminology Criteria  for Adverse 
Events (CTCAE) . Version 5.0 . Published: November 27, 2017 . 
 
Wen, C. C. et al. Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities  
against Severe Acute Respiratory Syndrome Coronavirus. J Med Chem . (2007).  
doi:10.1021/jm070295s  
 
Wieland, A. et al. Anticancer Effects of Niclosamide in Human Glioblastoma. Clin Ca ncer Res . 
(2013). doi: 10.1016/j.cellsig.2017.04.001  
 
Wilder -Smith, A. et al. Can we contain the COVID -19 outbreak with the same measures as for  
SARS? Lancet. Infect. Dis . (2020). doi:10.1016/S1473 -3099(20)30129 -8  
 
World Health Organization, Executive Summary, Safety Review of Niclosamide, Pyrantel,  
Triclabendazole and Oxamniquine (2004)  
 
World Health Organization, Model List of Essential Medicines, 21 st  List (2019). 
http://www.who.int/medicines/publications/essentialmedicines/en/  
 
Wu, C. J. et al. Inhibition of severe acute respiratory syndrome coronavirus replication by  
niclosamide. Antimicrob. Agents Chemother . (2004). doi:10.1128/AAC.48.7.2693 -2696.  2004  
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 48 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Xu, J. et al. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS 
Infect. Dis . (2020). doi:10.1021/acsinfecdis.0c00052  
 
Yeh, H. H. et al. Upregulation of Tissue Factor by Activated Stat3 Contributes to Malignant  
Pleural Effusion Generation via Enhancing Tumor Metastasis and Vascular Permeability in Lung  
Adenocarcinoma. PLoS One . (2013). doi: 10.1371/journal.pone.0075287  
 
Yu , H. et al. Crosstalk between cancer and immune cells: role of STAT3 in the tumour  
microenvironment. Nat Rev Immunol . (2020). doi: 10.1038/nri1995  
 
Zhang, Y. Y. et al. Design and evaluat ion of injectable niclosamide nanocrystals prepared by wet  
media milling technique. Drug Dev Ind Pharm.  (2015). doi: 10.3109/03639045.2014.954585  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 49 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 12. Appendices  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 50 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Appendix 1 : Abbreviations and Terms  
ANA  ANA Therapeutics, Incorporated  
API  Active pharmaceutical ingredient  
ARDS  Acute respiratory distress syndrome  
AUC  Area under curve  
BID  Twice daily  
BSL Bio-safety Level  
CL  Clearance  
Cmax  Maximum serum concentration  
CoV  Coronavirus  
COVID -19  Coronavirus disease of 2019  
CYP  Cytochrome P450  
DG  Dose group  
DLT  Dose -limiting toxicity  
DMC  Data monitoring committee  
DMSO  Dimethylsulfoxide  
DP  Drug product  
DS  Drug substance  
EC50  Half-maximal effective concentration  
ECMO  Extracorporeal membrane oxygenation  
IC50  Half-maximal inhibitory concentration  
FDA  Food and Drug Administration  
GI  Gastrointestinal  
GLP  Good laboratory practice  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 51 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 HDPE  high-density polyethylene  
HTD  Human therapeutic dose  
ICH  International Council for Harmonization of Technical Requirements for  
Pharmaceuticals for Human Use  
IL  Interleukin  
LD50  Half-maximal lethal dose  
LLN  Lower limit of normal  
MERS  Middle East respiratory syndrome  
MRT  Mean residence time  
NA Not applicable  
NDA  New drug application  
NF-kB  Nuclear factor kappa -light-chain -enhancer of activated B cells  
PBS  Phosphate buffered saline  
PK  Pharmacokinetic  
PO  By mouth  
PVA  Polyvinyl alcohol  
SAE  Serious adverse event  
SARS  Severe acute respiratory syndrome  
SBA  Summary basis for approval  
STAT  Signal transducers and activators of transcription  
SUSAR  Suspected unexpected serious adverse reaction  
t1/2  Elimination half -life  
TID  Thrice daily  
tmax  Time take to reach Cmax  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 52 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 TMEM16A  Transmembrane member 16A  
TNF -α  Tumor necrosis factor -alpha  
ULN  Upper limit of normal  
VSS  Volume of distribution at steady state  
WBC  White blood cell  
WHO  World Health Organization   
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 53 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Appendix  2: Clinical Laboratory Tests  
• The tests detailed in Table 4 will be performed by the local laboratory.  
• Additional tests may be performed at any time during the study as determined necessary 
by the Investigator  or required by local regulations . 
Table 4  Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Platelet Count   RBC Indices : 
MCV  
MCH  
% Reticulocytes  WBC C ount with 
Differential : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  RBC Count  
Hemoglobin  
Hematocrit  
Clinical 
Chemistry  BUN  
Calcium  
Creatinine  Glucose  
Potassium  
Sodium  Total and direct 
bilirubin  
Total Protein  
Aspartate Aminotransferase  (AST ) 
Alanine Aminotransferase (ALT ) 
Alkaline phosphatase  
Routine 
Urinalysis  • Specific gravity  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, 
leukocyte esterase by dipsti ck 
• Microscopic examination (if blood or protein is abnormal)  
Other 
Screening 
Tests  • Urine a lcohol and drug screen s (to include at minimum: amphetamines, 
barbiturates, cocaine, opiates, cannabinoids and benzodiazepines)  
• Serum human chorionic gonadotropin ( hCG ) pregnancy test at Screening 
and urine pregnancy test on Day -1 for women of child bearin g potential  
• Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and 
hepatitis C virus antibody or specify other tests)  
Investigator s must document their review of each laboratory safety report.  
 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 54 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Appendix 3: Study Governance Considerations  
Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with  the following : 
• Consensus ethic al principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH G ood Clinical Practice  (GCP) Guidelines  
• Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigator  Brochure , and other relevan t 
documents ( e.g., advertisements) must be submitted to an IRB/IEC by the Investigator  
and reviewed and approved by the IRB/IEC before the study is initiated.   
• Any amendments to the protocol will require IRB /IEC approval before  implementation of 
changes ma de to the study design, except for changes necessary to eliminate an 
immediate hazard to study participant s.  
• The Investigator  will be  responsible for  the following : 
o Providing written summaries of the status of the study to the IRB/ IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/ IEC 
o Notifying the IRB/IEC of SAE s or other significant safety findings as required by 
IRB/IEC procedures  
o Providing oversight of the  conduct of the study at the site and adherence  to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies  (if applicable), and all other applicable local regulations  
Financial Disclosure  
Investigator s and sub -Investigator s will provide t he Sponsor  with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities.  Investigator s are 
responsible for provi ding information on financial interests during the course of the study and for 
1 year  after completion of the study.  
Informed Consen t Process  
• The Investigator  or his/her representative will explain the nature of the study to the 
participant  or his/her legally authorized representative and answer all questions regarding 
the study.  
• Participant s must be informed that their participation is voluntary. Participant s will be 
required to sign a statement of  informed consent that meets the requirements of 21  CFR 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 55 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability 
Act ( HIPAA ) requirements , where applicable , and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained 
before the participant  was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
• Participant s must be re -consented to the most current version of the ICF(s)  during th eir 
participation in the study.  
• A copy of the ICF(s)  must be provided to the participant  or the participant ’s legally 
authorized representative.  
Data Protection  
• Participants will be assigned a unique identifier by the Sponsor . Any participant records 
or datasets that are transferred to the Sponsor  will contain the identifier only; participant 
names or any information which would make the participant identifiable w ill not be 
transferred.  
• The participant must be informed that his/her personal study -related data will be used by  
the Sponsor  in accordance with local data protection law. The level of  disclosure must 
also be explained to the participant.  
• The participant  must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
Sponsor , by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.  
Dissemination of Cl inical Study  Data  
A clinical study report will be prepared with reference to ICH Guidance E3 to include:  
• details of where the study was carried out,  
• dates of the start and completion of each period of the study,  
• details of the investigational product (IP) and a statement of production will be provided 
by ANA Therapeutics, Inc.,  
• a statement confirming that the applicable IRB/IEC gave written approval for the study in 
accordance with local regulations,  
• a demographic listing for al l participants,  
• a list of all AEs according to IP,  
• details of any occurrences which may be of significance to the study outcome,  
• details of all operations, calculations and transformations performed on the reported data,  
• the SAP and report will be produced  by ANA Therapeutics,  Inc. or their agents and will be 
incorporated into the final report , 
• all data from any withdrawn participant not included in the statistical analysis,  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 56 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • a scientific interpretation of the results,  
• a description of the study methods used . 
Consideration will be given to any comments on a draft report. The report will incorporate the 
analytical and statistical results and methods produced by the Sponsor  or their agents. A final 
report will be prepared to contain all those sections in the dr aft and a statement of compliance 
covering all the areas of the study conducted at the investigational site and the report, with GCP. 
The report will be issued under the Sponsor ’s responsibility.  
Where required by the applicable regulatory requirements, an  Investigator  signatory will be 
identified for the approval of the clinical study report. The Investigator  will be provided reasonable 
access to statistical tables, figures, and relevant reports and will have the opportunity to review 
complete study result s. The Sponsor  will also provide the Investigator  with the full summary of 
study results.  
Data Quality Assurance  
All participant  data relating to the study will be reco rded on printed or electronic CRF unless 
transmitted to the Sponsor  or designee electron ically ( e.g., laboratory data). The Investigator  is 
responsible for verifying that data entries are accurate and correct by physically or electronically 
signing the CRF.  
The Investigator  must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections  and provid e direct access to source data  documents.  
The Sponsor  or designee is responsible for the data management of this study including quality 
checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participant s are being protected ; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
Records and documents, including signed ICF s, pertaining to the conduct of this  study must be 
retained by the Investigator  for 5 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without  the written approval of the  Sponsor . No records may be transferred to 
another location or party without written notification to the Sponsor .  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 57 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Source Documents  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected.  Source documents are filed at the Investigator ’s site. 
Data reported on the CRF  or entered in the eCRF  that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
Investigator  may nee d to request previous medical records or transfer records, depending  on the 
study . Also, current medical records must be available.  
Study and Site Closure  
The Sponsor  designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the Sponsor . Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and  study supplies 
have been collected and a study -site closure visit has been performed . 
The Investigator  may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the Sponsor  or Investigator  may include but are 
not limited to:  
• Failure of the Investigator  to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the Sponsor ’s procedures, or GCP guidelines  
• Inadequate recruitment of participant s by the Investigator  
• Discontinuation of further study treatment development  
  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 58 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Appendix 4: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
Definition of an Adverse Event ( AE) 
AE Definition  
• An AE is any untoward medical occurrence in a patient  or clinical study participant , 
temporally associated with the use of study treatment , whether or not considered 
related to the study treatment . 
• NOTE: An AE can therefore be any  unfavorable  and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study tr eatment . 
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology , clinical chemistry, or urinalysis) 
or other safety assessments ( e.g., ECG , radiological scans, vital signs 
measurements), including those that worsen from baseline, considered  clinically 
significant by the Investigator  per Appendix 6  (i.e., not related to progression  of 
underlying disease ). 
• Exacerb ation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even 
though it may have been present before  the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication . Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent.  Such overdoses  should be r eported regardless of sequelae.  
 
Events NOT  Meeting the AE D efinition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
Investigator  to be more severe than expected for the participant ’s condition.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 59 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • The disease/di sorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant ’s condition.  
• Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE. 
• Situations in which  an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
 
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( e.g., hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant  was at risk of death at the time of the event.  It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
c. Requ ires inpatient  hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the participant  has been detained (usually 
involving at least an overnight stay) at the hospital  or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting.  Complications that occur during hospitalization are AE s. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious . When in doubt as to whether “hospitalization” occurred or was necessary, the A E 
should be considered serious.  
Hospitalization for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 60 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as u ncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( e.g., sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption . 
e. Is a congenital anomaly/birth defect  
f. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospitalization but may 
jeopardize the participant  or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition.  These events should usually  
be considered serious . 
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse . 
Recording and AE and /or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all  
documentation ( e.g., hospital progress notes, laboratory  reports , and diagnostics 
reports) related to the event.  
• The Investigator  will then record all relevant AE/SAE informa tion in the CRF . 
• It is not acceptable for the Investigator  to send photocopies of the participant ’s 
medical records to ANA Therapeutics  in lieu of completion of the AE/SAE CRF 
page.  
• There may be instances when copies of medical records for certain cases are 
requested by ANA Therapeutics . In this case, all participant  identifiers, with the 
exception of the participant  number, will be redacted  on the copies of the medical 
records before  submission to ANA Therapeutics . 
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 61 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • The Investigator  will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible , the diagnosis (not 
the individu al signs/symptoms) will be documented as the AE/SAE . 
Assessment of Intensity  
The Investigator  will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories:   
• Mild:  An event that is easil y tolerated by the participant , causing minimal discomfort 
and not interfering with everyday activities.  
• Moderate:  An event that causes  sufficient discomfort and interfere s with normal 
everyday activities . 
• Severe:  An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with a  SAE. Severe is a category utilized for rating the 
intensity of an event; and both AE s and SAE s can be assessed as severe.  
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE , NOT when it is rated  as severe.  
 
Assessment of Causality  
• The Investigator  is obligated to assess the relationship between study treatment and 
each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship convey s that there are facts , evidence , 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The Investigator  will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease (s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
• The Investigator  will also consult the Investigator ’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.  
• For each AE/SAE , the Investigator  must  document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 62 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • There may be situations in which an SAE has occurred and the Investigator  has 
minimal information to include i n the initial report to ANA Therapeutics . However, 
it is very important that the Investigator  always make an assessment of 
causality for every event before  the initial transmission of the SAE data to ANA 
Therapeutics . 
• The Investigator  may change his/her opinion of causality in light of follow -up 
information  and send a  SAE follow -up report with the updated causality assessment . 
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AE s and SAE s 
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by ANA 
Therapeutics  to elucidate the nature and/or causality of the AE or SAE  as fully as 
possible . This may include additional laboratory tests or investigations, 
histopathological examinations , or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized foll ow-
up period, the Investigator will provide ANA Therapeutics  with a copy of any post -
mortem findings including histopathology.  
• New or updated information will be recorded in the originally completed CRF.  
• The Investigator  will submit any updated SAE data to the ANA Therapeutics  within 
24 hours of receipt of  the information . 
 
Reporting of SAE s 
SAE Reporting to ANA Therapeutics  via an Electronic Data Collection Tool 
• The p rimary mechanism for reporting an SAE  to ANA Therapeutics  will be the 
electronic data collection tool . 
• If the electronic system is unavailable for more than 24 hours, the n the  site will use 
the paper SAE data collection tool (see next section) . 
• The s ite will enter the SAE  data into the electronic system as soon as it becomes 
available.  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 63 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data . 
• If a site receives a report of a new SAE from a study participant  or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, the n the  site can report this information on a paper SAE form  (see 
next section ) or by telephone.  
• Contacts for SAE reporting can be found  in the Study Manual . 
 
SAE Reporting via Paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the SAE coordinator . 
• In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable with a copy of the SAE data co llection tool sent by overnight 
mail or courier service.  
• Initial notification via telephone does not replace the need for the Investigator  to 
complete and sign the SAE CRF pages withi n the designated reporting time frames.  
• Contacts for SAE reporting can be  found  in the Study Manual.  
  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 64 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Appendix  5: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions  
Woman of Child bearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below) . 
Women in the following cate gories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
Note:  Docum entation can come from the site personnel’s: review of the participant ’s 
medical records, medical examination, or medical history interview.  
 
3. Postmenopausal  female  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be us ed to confirm a post menopausal state in women not 
using hormonal contraception or hormonal replacement therapy (HRT). However , in 
the absence of  12 months of amenorrhea, a single FSH measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non-hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before  study enrollment . 
Contracept ion Guidance  
Male  participants  
• Male participa nts with female partners of childbearing potential are eligible to 
participate if they agree to ONE of the following [during the protocol -defined time 
frame in Section 6.1]:  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 65 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle (abstinent on a 
long term and persistent basis ) and agree to remain abstinent  
• Agree to use a male condom plus partner use of a contraceptive method with a failure 
rate of <1% per year as described in Table 5 when having penile -vaginal intercourse 
with a woman of childbearing potential  who is not currently pregnant  
Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile -vaginal 
intercourse or use a male condom during each episode of penile penetration [during the protocol -
defined time frame]   
Refrain from donating sperm for the duration of the study and for 30 days  after t he last dose of 
study treatment . 
Female participants  
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table 5. 
 
Table 5:  Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent a  
Failure rate of <1% per year when used consistently  and correctly.   
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulationb  
• Oral  
• Intravaginal  
• Transdermal  
• Progestogen only hormonal contraception associated with inhibition of ovulation  
• Oral  
• Injectable  
Highly Effective Methods That Are User Independent a  
Implantable progestogen only hormonal contraception associated with inhibition of ovulationb 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
Bilateral tubal occlusion  
• Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.   
• Sexual abstinence  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 66 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatmen t. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the participant.   
NOTES:  
a) Typical use failure rates may differ from those when used consistently and correct ly. Use 
should be consistent with local regulations regarding the use of contraceptive methods for 
participants participating in clinical studies.  
b) Hormonal contraception may be susceptible to interaction with the study treatment, which 
may reduce the efficacy of the contraceptive method. In this case, two highly effective 
methods of contraception should be utilized during the treatment period and for at least 30 
days after the last dose of study treatment  
 
Pregnancy Testing  
• WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive pregnancy test . 
• Pregnancy testing will be performed whenever a menstrual cycle  is missed or when 
pregnancy is otherwise suspected  
Collection of Pregnancy Information  
Male participant s with partners who become pregnant  
• The Investigator  will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This applies 
only to male participants who receive active study treatment . 
• After obtaining the necessar y signed informed consent from the pregnant female partner 
directly, the Investigator  will record pregnancy information on the appropriate form and 
submit it to the Sponsor  within 24 hours of learning of the partner’s pregnancy. The female 
partner will als o be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and child will be forwarded to the Sponsor . Generally, the follow -up will 
be no longer than 6 to 8  weeks following the estimated delivery date. Any termination  of the 
pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or 
indication for the procedure.   
Female Participants who become pregnant  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 67 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 • The Investigator  will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate 
form and submitted to the Sponsor  within 24 hours of learning of a participant's pregnancy.  
The participant will be followed to determine the outcome of the pregnancy. The Investigator  
will collect follow -up information on the participant and the neonate and the information will 
be forwarded to the Sponsor . Generally, follow -up will not be requi red for longer than 6 to 8 
weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, 
regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
• While pregnancy itself is not considered to b e an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion 
is always considered to be an SAE and will be reported as such. Any post -study pregnancy -
related SAE considered reaso nably related to the study treatment by the Investigator  will be 
reported to the Investigator  as described in Section 9.2. While the Investigator  is not obligated 
to actively seek this information in former study participants, he or she may learn of an SAE 
through spontaneous reporting.   
• Any female participant w ho becomes pregnant while participating in the study will be 
withdrawn from the study  
  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 68 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Appendix 6: Potentially Clinically Significant Laboratory Criteria  
(Local Laboratory Results)  
Parameter  SI Unit  Lower 
Limit  Higher Limit  % Decrease 
from Bio-
safety Leve l 
(BSL ) % Increase 
from BSL  
CHEMISTRY  
Blood Urea Nitrogen 
(BUN)  mmol/L  NA >1.5 *ULN  NA >100  
Creatinine  mg/dL  NA >1.5 *ULN  NA >50 
Sodium  mmol/L  <0.85 *LLN  >1.1 *ULN  >10 >10 
Potassium  mol/L  <0.8 *LLN  >1.2 *ULN  >20 >20 
Chloride  mmol/L  <0.8 *LLN  >1.2 *ULN  >20 >20 
Carbon Dioxide 
(Bicarbonate)  mmol/L  <0.7 *LLN  >1.3 *ULN  >40 >40 
Glucose  mmol/L  <0.6 *LLN  >3.0 *ULN  >40 >200  
Total Bilirubin  mg/dL  NA >2.5 *ULN  NA >150  
Direct Bilirubin  mg/dL  NA >1.5 *ULN  NA >150  
Alkaline Phosphatase  U/L <0.5 *LLN  >2.0 *ULN  >80 >100  
Aspartate 
Aminotransferase 
(AST)  U/L NA >3.0 *ULN  NA >200  
Alanine 
Aminotransferase 
(ALT)  U/L NA >3.0 *ULN  NA >200  
HEMATOLOGY  
Hematocrit  Ratio  <0.8 *LLN  >1.3 *ULN  >20 >30 
Hemoglobin  g/L <0.8 *LLN  >1.3 *ULN  >20 >30 
Platelet Count  109/L <0.65 *LLN  >1.5 *ULN  >50 >100  
White Blood Cell Count  109/L <0.65 *LLN  >1.6 *ULN  >60 >100  
Neutrophils, absolute 
cell count  109/L <0.65 *LLN  >1.6 *ULN  >75 >100  
CONFIDENTIAL   ANA Therapeutics  
Protocol  ANA001  
Page 69 of 69 
 
Status: Final v2.0; Date 0 9Jan2021  
 Parameter  SI Unit  Lower 
Limit  Higher Limit  % Decrease 
from Bio-
safety Leve l 
(BSL ) % Increase 
from BSL  
Lymphocytes, absolute 
count  109/L <0.25 *LLN  >1.5 *ULN  >75 >100  
Eosinophils, absolute 
count  109/L NA >4.0 *ULN  NA >300  
Monocytes, absolute 
count  109/L NA >4.0 *ULN  NA >300  
Basophils, absolute 
count  109/L NA >4.0 *ULN  NA >300  
COAGULATION  
Partial Thromboplastin 
Time (aPTT)  sec <0.5 *LLN  >2.0 *ULN  >100  >100  
Prothrombin Time (PT)  sec <0.5 *LLN  >2.0 *ULN  >100  >100  
International 
Normalized Ratio (INR)  Ratio  <0.5 *LLN  >2.0 *ULN  >100  >100  
LLN:  Lower limit of normal value provided by the local laboratory  
ULN: Upper limit of normal value provided by the local laboratory  
 